An innovative virtual multi-institutional, multidisciplinary neuro-oncology tumor board: The Nih-Nob experience during the COVID-19 pandemic
Recommended Citation
Rogers J, Acquaye A, Ikiddeh-Barnes U, Benson K, Boris L, Akindona F, Frederico S, Jammula V, Kim Y, Timmer M, Aboud O, Avgeropoulos N, Burton E, Cachia D, Camphausen K, Colman H, Dixit K, Drappatz J, Dunbar E, Forsyth P, Komlodi-Pasztor E, Mandel J, Lee EQ, Ranjan S, Lukas R, Salacz M, Smith-Cohn M, Snyder J, Wooley J, Chaudhry H, Theeler B, Tsien C, Smirniotopoulos J. An innovative virtual multi-institutional, multidisciplinary neuro-oncology tumor board: The Nih-Nob experience during the COVID-19 pandemic. Neuro Oncol 2021; 23(SUPPL 6):vi111.
Document Type
Conference Proceeding
Publication Date
11-12-2021
Publication Title
Neuro Oncol
Abstract
BACKGROUND: The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions, we expanded our existing MTB by transitioning to a virtual format that maintained our commitment to providing consultation for primary CNS tumor cases. This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. Here, we describe results from opening our MTB remotely to these teams. METHODS: We retrospectively reviewed records from remote MTB meetings held between April 2020 and March 2021. To gauge the impact of our MTB on clinical management, we administered a brief survey querying BTTC members. RESULTS: Twenty-eight providers presented 41 cases during 24 virtual MTB meetings (range: 1-4 cases per meeting). Two cases (5%) were presented only for educational value. Approximately half (54%) of the cases discussed dealt with diagnosis/management of an NCI-CONNECT rare CNS tumor. During MTB discussions of the 39 cases seeking diagnosis/management recommendations, 32% received clinical trial recommendations, 10% were suggested to enroll in the NCI Neuro-Oncology Branch (NOB) Natural History Study (NCT02851706), 17% received a recommendation to obtain central neuropathology review, and 100% received recommendations for further disease management. Most BTTC survey respondents (83%) found these recommendations impactful in the management/treatment of their presented case or generally useful/ informative for their clinical practice. CONCLUSION: We describe the feasibility and utility of an innovative virtual multi-institutional MTB. These novel remote meetings allowed for discussion of complex neuro-oncology cases and recommendations from experts, particularly important for those with rare CNS tumors. Our study's findings during the COVID-19 pandemic of the value of providing remote access to MTBs should apply postpandemic.
PubMed ID
Not assigned.
Volume
23
Issue
SUPPL 6
First Page
vi111
